EGFR, a growth factor receptor that is often regulated through the autocrine growth factor loop in normal bronchial epithelial cells and lung cancer cells [120], was investigated in a phase II study by Ichihara et al., where gefitinib in combination with bevacizumab was administered as a potential first-line therapy for patients with non-small-cell-lung cancer with EGFR mutations. The gene discussed is EGFR; the disease is lung cancer.